ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares ...

ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high cancers including colorectal, endometrial, ovarian, and gastric tumors.

Bayer announced new post-hoc analyses from the Phase III ARANOTE trial, showing that darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) improved health-related quality of life (HRQoL) and ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical advancements in the field of CAR-T therapies, specifically on MB-105, a novel ...

The European Commission has approved a perioperative regimen of Bristol Myers Squibb’s immunotherapy drug Opdivo® (nivolumab) for adults with resectable, high-risk non-small cell lung cancer (NSCLC) ...

The START Center for Cancer Research dosed the first patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent mRNA-based cancer vaccine targeting advanced solid tumors.

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology Training Programs, a newly created post that reflects the organisation’s ...

The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously treated non-squamous NSCLC with high c-Met overexpression. Backed by Phase 2 ...

The Innovation-Implementation Divide What the Index underscores is not a failure of scientific progress, but rather the growing complexity of applying that progress in real-world clinical care. Three ...